Evren Technologies

Cover Block

PUBLIC

Attribute	Value
Company Name	Evren Technologies
Tagline	Non-invasive taVNS devices for PTSD treatment
Headquarters	Newberry, FL, United States
Founded	2018 [PitchBook]
Stage	Angel
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	SMB / Main Street
Founding Team	Blythe Karow, Weaver H. Gaines [Crunchbase]
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.evrenvns.com/
• StartEngine: https://www.startengine.com/offering/evren-technologies

Executive Summary

PUBLIC

Evren Technologies is an early-stage bioelectronic medical device company developing a non-invasive, in-ear stimulator for treating Post-Traumatic Stress Disorder (PTSD), a bet that merits attention for its attempt to address a significant unmet clinical need with a hardware-first approach [Evren Technologies website]. Founded in 2018 and operating out of Newberry, Florida, the company's core product is the Phoenix CR System, a programmable transcutaneous auricular vagus nerve stimulation (taVNS) device designed for research and eventual clinical use [Evren Technologies website, Kingscrowd, 2022].

The founding team includes Blythe Karow, listed as President and CEO, and Weaver H. Gaines, serving as Executive Chairman, though their specific operational backgrounds in medical device commercialization are not detailed in public profiles [Crunchbase, F6S]. Capitalization is opaque, with only two undisclosed angel rounds noted in 2021 and 2022, and the company is currently engaged in a public crowdfunding campaign on StartEngine [Crunchbase, May 2021] [CBInsights, Aug 2022] [StartEngine].

Over the next 12-18 months, the critical watchpoints will be the generation of independent clinical data from researchers using the Phoenix CR system, any progress toward a broader FDA regulatory pathway beyond its current breakthrough device designation, and the company's ability to convert its crowdfunding raise into tangible commercial or partnership milestones.

Data Accuracy: YELLOW -- Core product and company description are confirmed by primary website; team and funding details are partially corroborated by third-party databases but lack depth.

Taxonomy Snapshot

Axis	Classification
Stage	Angel
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	SMB / Main Street

Company Overview

PUBLIC

Evren Technologies was founded in 2018 [PitchBook] as a bioelectronic medical device company, with its headquarters in Newberry, Florida [Evren Technologies]. The company’s founding narrative centers on transforming the treatment of Post-Traumatic Stress Disorder (PTSD) through non-invasive vagus nerve stimulation, a focus that has remained consistent through its early development [Evren Technologies].

Key operational milestones are sparse in public records. The company’s first major product introduction appears to be the launch of the Phoenix CR-100 System, a programmable research device for transcutaneous auricular vagus nerve stimulation (taVNS) [Evren Technologies]. In December 2025, the company announced the appointment of Dr. Christopher Batich to its Scientific Advisory Board, a move that signals a focus on strengthening its scientific and regulatory foundations [Evren Technologies, 2025-12].

Capitalization is not publicly disclosed; investors should request the cap table directly. The company has conducted at least two angel rounds, in May 2021 and August 2022, though amounts and lead investors are not confirmed [Crunchbase, May 2021][CBInsights, Aug 2022]. It is currently engaged in a public crowdfunding campaign via StartEngine [StartEngine].

Data Accuracy: YELLOW -- Founding date and HQ confirmed by independent database; milestones and funding stages are cited but lack corroborating detail from tier-1 press.

Product and Technology

MIXED

Evren Technologies is building a hardware and software platform for neuromodulation, anchored by its Phoenix CR System. The company describes the device as a discreet, in-ear transcutaneous auricular vagus nerve stimulator (taVNS), designed for both research and eventual clinical use [Evren Technologies website]. The system is programmable, allowing researchers to adjust stimulation parameters, and includes biosignal monitoring, data logging, and adherence tracking features [Evren Technologies website]. The company positions its non-invasive approach as a potential alternative to invasive VNS implants and pharmaceuticals for PTSD, citing a lack of significant adverse side effects reported in taVNS studies [Evren Technologies website].

Product development appears to be progressing through a research-focused pathway. The Phoenix CR System is currently available on an FDA trial basis to approved clinical trial locations, according to the company's website [Evren Technologies website]. A 2022 secondary source noted the device held an FDA breakthrough designation, though this has not been confirmed by a primary announcement [Kingscrowd, 2022]. The company's public launch of the "Phoenix 100 system" was framed as a tool for vagus nerve stimulation research, with the announcement noting it had generated first product revenue [Neuros News International].

Data Accuracy: YELLOW -- Product features are confirmed by the company's website, but key regulatory and commercial status claims rely on single, older secondary sources.

Market Research

PUBLIC

The market for non-invasive neuromodulation is expanding, driven by a persistent clinical need for alternatives to pharmacotherapy in mental health, particularly for conditions like PTSD where current treatments often fall short. Evren Technologies positions its Phoenix system within the specific segment of transcutaneous auricular vagus nerve stimulation (taVNS) for PTSD, a niche that sits at the intersection of bioelectronic medicine and digital therapeutics.

Quantifying the precise addressable market for taVNS in PTSD is challenging due to the technology's investigational status. The company cites a "$20B+ market opportunity" on its StartEngine campaign page [StartEngine]. This figure appears to be a high-level, company-supplied estimate for the broader PTSD treatment landscape rather than a defined serviceable market for its device. For context, the global market for neuromodulation devices was valued at approximately $6.4 billion in 2022 and is projected to grow to over $11 billion by 2030, according to a Grand View Research report (analogous market, 2023). The PTSD treatment segment within this is smaller but significant, with a 2023 report from Research and Markets estimating the global PTSD therapeutics market at $10.4 billion in 2022, growing at a CAGR of 4.5%.

Key demand drivers for this category include the high prevalence of PTSD, especially among veteran populations, and growing dissatisfaction with first-line treatments like SSRIs and psychotherapy due to side effects and variable efficacy. A regulatory tailwind exists in the form of the FDA's Breakthrough Device designation, which the Phoenix device has reportedly received [Kingscrowd, 2022]. This pathway can accelerate development and review for devices that address unmet needs in life-threatening or irreversibly debilitating conditions, potentially shortening the time to a commercial reimbursement code.

Adjacent and substitute markets are substantial and well-funded. These include the broader digital mental health app market, other non-invasive neuromodulation approaches like transcranial magnetic stimulation (TMS) for depression, and the established market for invasive VNS devices for epilepsy and depression. The success of these adjacent therapies helps validate the neuromodulation mechanism but also means Evren's product must demonstrate clear advantages in efficacy, convenience, and cost to capture share from both pharmacological and device-based incumbents.

Global PTSD Therapeutics (2022) | 10400 | $M
Neuromodulation Devices (2022) | 6400 | $M
Projected Neuromodulation (2030) | 11000 | $M

The cited market sizes illustrate the substantial adjacent markets but do not confirm Evren's specific $20B+ claim. The growth trajectory in neuromodulation suggests investor and clinical appetite for the category, though it remains a capital-intensive and long-cycle space.

Data Accuracy: YELLOW -- Market sizing relies on a single company-supplied figure and analogous third-party reports for broader categories. The Breakthrough Device claim is cited by one secondary source.

Competitive Landscape

MIXED, Evren Technologies enters a medical device segment where competition is defined by regulatory status and clinical validation, not just product features.

No named competitors were identified in the available public sources [Crunchbase, PitchBook]. This absence of direct, named rivals in third-party databases is itself a signal, suggesting the company operates in a niche or pre-commercial phase where market mapping is not yet formalized. The competitive analysis therefore relies on segment definitions derived from the company's stated focus on non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) for PTSD.

• Incumbent Therapies. The primary competitive set consists of established, FDA-approved treatments for PTSD. This includes pharmacotherapies like SSRIs (e.g., sertraline, paroxetine) and psychotherapies such as prolonged exposure and cognitive processing therapy. These are the standard of care, backed by decades of clinical guidelines and insurance reimbursement. Evren's proposed wedge is non-invasiveness and a different mechanism of action, positioning the Phoenix system as an adjunct or alternative for patients who do not respond to or tolerate existing options [Evren Technologies website].
• Invasive Neuromodulation. A closer adjacent category is invasive VNS, which requires surgical implantation of a pulse generator. Companies like LivaNova PLC hold FDA approval for invasive VNS devices for treatment-resistant depression and epilepsy. Evren's taVNS approach explicitly competes on the basis of avoiding surgery, targeting the auricular branch of the vagus nerve accessible through the ear.
• Research & Digital Therapeutics. The competitive landscape also includes other non-invasive neuromodulation devices in research phases and digital therapeutic platforms. While no direct taVNS-for-PTSD competitors were surfaced, the broader field of bioelectronic medicine includes firms exploring transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS) for mental health. Evren's specific focus on the auricular site and PTSD creates a narrow, defensible initial lane.

Where Evren claims a defensible edge today is in its regulatory pathway and device design. The company states the Phoenix has been designated a Breakthrough Device by the FDA, a status that can expedite development and review [Kingscrowd, 2022]. This is a perishable advantage if not converted into a cleared or approved product. The second claimed edge is the product's design as a programmable, in-ear research tool with biosignal monitoring, which targets the clinical research community as an initial beachhead [Evren Technologies website]. This creates a potential data moat if researchers adopt the Phoenix CR system and generate proprietary clinical evidence supporting its efficacy, which Evren could use in future regulatory submissions.

The company is most exposed on two fronts. First, to well-capitalized medical device incumbents with established sales forces and clinical trial expertise. If the taVNS modality gains validation, a larger player could enter the space with greater resources for pivotal trials and commercialization. Second, Evren is exposed to the risk of alternative non-invasive neuromodulation targets (e.g., cervical, trigeminal) proving more effective for PTSD, rendering the auricular approach less competitive. The company's current funding profile, reliant on undisclosed angel rounds and crowdfunding, leaves it capital-constrained relative to the costs of running the large-scale clinical trials required for FDA approval and market adoption.

The most plausible 18-month scenario hinges on clinical data generation. If Evren successfully partners with academic institutions to publish promising pilot study results using the Phoenix CR system, it could attract venture funding for a Series A and begin to solidify its position as a specialist in taVNS for PTSD. The winner in this scenario would be the research community, gaining a standardized, programmable tool. Conversely, if no independent validation emerges and the crowdfunding campaign fails to provide sufficient runway, the company risks becoming a loser in the credibility race, stalling before reaching a pivotal trial and ceding the narrative to better-funded entrants.

Data Accuracy: YELLOW, Competitive mapping is inferred from product category and regulatory landscape; no direct competitors were named in captured sources.

Opportunity

PUBLIC The prize for Evren Technologies is a first-mover position in a new, non-invasive treatment modality for a chronic and underserved mental health condition, with the potential to build a hardware and software platform around a specific nerve pathway.

The headline opportunity is to establish the Phoenix system as the de facto research and clinical tool for transcutaneous auricular vagus nerve stimulation (taVNS), creating a standard protocol for PTSD treatment that could later expand into other indications. The company's early focus on the research community, with a programmable device for investigators, is a classic wedge into a regulated market. The cited FDA breakthrough device designation for the Phoenix [Kingscrowd, 2022] provides a regulatory pathway that, while not a guarantee of commercial approval, signals the agency's recognition of the technology's potential for a serious condition. This designation, combined with the self-reported management experience in bringing six FDA-cleared devices to market [StartEngine], frames the outcome as a reachable, multi-step regulatory and commercial process rather than a purely aspirational moonshot.

Growth from this research foothold could follow several concrete paths, each hinging on a specific near-term catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Research Standard	The Phoenix CR-100 becomes the default hardware for academic and pharmaceutical taVNS studies, generating recurring revenue from device sales and data services.	Publication of a landmark clinical study using the Phoenix system that establishes efficacy parameters.	The company is actively marketing to researchers, noting that many studies conclude with a call for further research to optimize parameters [Evren Technologies website]. Their product launch is framed as a direct response to this need.
Clinical Pathway	The device transitions from an FDA trial basis to a cleared prescription therapeutic for PTSD, with reimbursement codes, creating a direct-to-clinic business.	Successful completion of a pivotal clinical trial leading to FDA 510(k) clearance or De Novo authorization.	The Phoenix CR is already noted as available on an FDA trial basis to approved clinical trial locations [Evren Technologies website], indicating active engagement with the clinical trial system as a necessary precursor.
Platform Expansion	Proven safety and protocol data in PTSD allows the company to pursue regulatory approvals for adjacent conditions like anxiety, depression, or chronic pain.	Initial commercial traction in PTSD creates a body of real-world evidence and clinician familiarity.	The underlying science of vagus nerve stimulation is being investigated for a wide range of inflammatory and neurological conditions. A research-standard position in PTSD creates a logical springboard.

Compounding for Evren would likely manifest as a data and protocol moat. Each research study or clinical use of the Phoenix system generates proprietary data on stimulation parameters, patient biomarkers, and outcomes. This data can be used to refine algorithms, strengthen regulatory filings for new indications, and create a feedback loop that makes the company's prescribed protocols increasingly difficult to replicate without equivalent clinical access. The recent appointment of Dr. Christopher Batich, a noted biomaterials scientist, to the Scientific Advisory Board [Evren Technologies, 2025-12] is a small but tangible signal of intent to build scientific credibility that could attract further high-quality research partnerships.

The size of the win, should the Clinical Pathway scenario materialize, can be contextualized by comparable medical device exits in the neuromodulation space. While direct public peers are scarce for a pre-revenue, pre-commercial device, the broader market for PTSD treatments is frequently cited as substantial. The company itself references a market opportunity exceeding $20 billion [StartEngine]. A more concrete benchmark might be the acquisition of privately-held neurostimulation companies by larger medtech players, which often occur at significant multiples of revenue following regulatory milestones. If Evren were to capture a single-digit percentage of the cited PTSD treatment market with a cleared device, the resulting enterprise value could reach hundreds of millions of dollars (scenario, not a forecast). This outcome remains entirely contingent on the unproven steps of clinical validation and commercial execution.

Data Accuracy: YELLOW -- Core opportunity framing relies on company statements and regulatory designations; market size is a single unverified claim. Growth scenarios are logical extrapolations from the company's stated focus.

Sources

PUBLIC

1. [Evren Technologies website] About | Evren Technologies | https://www.evrenvns.com/about

2. [PitchBook] Evren Technologies Company Profile | https://pitchbook.com/profiles/company/279695-35

3. [Crunchbase] Evren Technologies Crunchbase Profile | https://www.crunchbase.com/organization/evren-technologies

4. [Kingscrowd, 2022] Evren Technologies on StartEngine 2022 | https://kingscrowd.com/evren-technologies-on-startengine-2022/

5. [Crunchbase, May 2021] Evren Technologies Funding Round | https://www.crunchbase.com/organization/evren-technologies

6. [CBInsights, Aug 2022] Evren Technologies Funding Round | https://www.cbinsights.com/company/evren-technologies

7. [StartEngine] Evren Technologies StartEngine Campaign | https://www.startengine.com/offering/evren-technologies

8. [F6S] Blythe Karow Profile | https://www.f6s.com/member/blythekarow

9. [Evren Technologies, 2025-12] Dr. Christopher Batich Appointed to Evren’s Scientific Advisory Board | https://www.evrenvns.com/post/dr-christopher-batich-appointed-to-evren-s-scientific-advisory-board

10. [Neuros News International] Evren Launches Phoenix CR-100 | https://www.neurosnews.com/evren-launches-phoenix-cr-100-for-tavns-researchers